Challenges of Manufacturing the Expanding Range of Bi/Multispecific Modalities

Pharma’s Almanac [Q4 2019] | Dr Bernie Sweeney, Director, Research & Technology

The pharmaceutical industry is increasingly focused on the development of next-generation drug products that allow the targeted delivery of active ingredients with multiple functionalities, increasing both efficacy and safety. Bi- and multispecific antibodies are prime examples of new drug substances with the potential to offer higher potency combined with new mechanisms of action while also reducing the cost and time for drug development.

Lorem ipsum dolor sit amet